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ABSTRACT 
Tampereen ammattikorkeakoulu 
Tampere University of Applied Sciences 
Degree Programme in Laboratory Sciences 
 
LAMPUOTI, JARKKO: 
Characterization of Human Induced Pluripotent Stem Cells 
 
Bachelor's thesis 57 pages, appendices 6 pages 
December 2013 
Induced pluripotent stem cells (iPSC) are cells reprogrammed from somatic cells with a 
set of defined factors. Induced pluripotent stem cells have promising applications in cell 
and tissue modeling, drug screening, and possibly also in future regenerative therapies. 
IPS cells exhibit characteristics and potency similar to embryonic stem cells and similar 
methods are employed to characterize and differentiate them. The objective of this study 
was to confirm the quality of the iPS cell lines for use in research. The purpose of the 
study was to characterize qualitatively six iPS cell lines with respect to pluripotency using 
immunocytochemistry, polymerase chain reaction, and microscopy. 
 
The expression of viral transgenes, endogenous pluripotency markers, and germ layer 
related genes was studied with PCR after reverse transcription. The expression of 
pluripotency marker proteins was analyzed with indirect immunofluorescence staining. 
Cell colony morphology was assessed with visual microscopy. 
 
Each of the six cell lines were successfully characterized. All lines exhibited all or nearly 
all of the pluripotency markers and at least one marker for each germ layer. No transgene 
activity was observed. Colony morphology was characteristic for human pluripotent stem 
cells. 
 
The results indicated that all cell lines studied were pluripotent stem cell lines and may 
thus be applied in research protocols. The origin of problems encountered with individual 
samples in PCR remains unknown but may imply the need for additional examination. 
To further study the possible differences in the gene expression results with different 
concentrations, a high-yielding RNA extraction protocol must be devised. 
 
 
Key words: iPS, characterization, stem cells, immunofluorescence, PCR 
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TIIVISTELMÄ 
Tampereen ammattikorkeakoulu 
Laboratorioalan koulutusohjelma 
 
JARKKO LAMPUOTI: 
Ihmisen uudelleenohjelmoitujen pluripotenttien kantasolujen karakterisointi 
 
Opinnäytetyö 57 sivua, joista liitteitä 6 sivua 
Joulukuu 2013 
Indusoidut pluripotentit kantasolut (iPS-solut) ovat uudelleenohjelmoituja soluja, jotka 
on tuotettu kuljettamalla tietyt transkriptiotekijät erilaistuneeseen soluun. iPS-soluilla on 
lukuisia lupaavia käyttökohteita, kuten solu- ja kudosmallinnus, lääkeainetutkimukset 
sekä tulevaisuudessa mahdollisesti myös kliiniset hoidot. Indusoidut pluripotentit 
kantasolut ja alkion kantasolut ovat piirteiltään samankaltaisia ja niiden 
karakterisoinnissa ja erilaistamisessa hyödynnetään samoja menetelmiä. Tämän 
tutkimuksen tavoitteena oli varmistaa tutkimuksessa käytettävien iPS-solulinjojen laatu. 
Työn tarkoitus oli kvalitatiivisesti karakterisoida kuusi iPS-solulinjaa 
pluripotenssitekijöiden osalta käyttäen polymeraasiketjureaktiota, 
immunofluoresenssivärjäystä ja mikroskopointia. 
 
Työssä tutkittiin virusperäisten siirtogeenien, solujen omien pluripotenssigeenien sekä 
alkiokerrosten geenien ilmentymistä PCR-tekniikalla. Pluripotenssitekijöiden 
ilmentymistä proteiinitasolla tutkittiin immunofluoresenssivärjäyksellä. Solukolonioiden 
muoto tutkittiin mikroskoopilla. 
 
Kaikki karakterisoidut solulinjat ilmensivät lähes kaikkia tutkittuja pluripotenssitekijöitä. 
Virusperäiset siirtogeenit eivät olleet aktiivisia. Kolonioiden morfologia oli 
pluripotenteille kantasoluille tyypillinen. 
 
Saatujen tulosten perusteella kaikki tutkitut solulinjat ovat pluripotentteja 
kantasolulinjoja ja niitä voidaan käyttää tutkimuksessa. PCR-analyyseihin liittyneiden 
ongelmien syitä ei tiedetä, mutta menetelmää voidaan tarvittaessa pyrkiä kehittämään. 
Geeniekspression erojen vertailemiseksi eri RNA-konsentraatioilla tulee kehittää 
paremman saannon tuottava eristysmenetelmä. 
 
Asiasanat: iPS, karakterisointi, kantasolu, PCR, immunofluoresenssi 
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1 INTRODUCTION 
 
 
Induced pluripotency refers to a condition where normally non-pluripotent somatic cells 
are forced to regress into a pluripotent state. First demonstrated by professor Yamanaka 
and his team with mouse fibroblasts and subsequently with human fibroblasts, induced 
pluripotency has become a prominent tool in biomedical research. (Takahashi & 
Yamanaka 2006; Takahashi et al. 2007.) 
 
This thesis was done at the Heart research group in the Institute of Biomedical 
Technology at the University of Tampere. The group exploits and differentiates patient-
specific induced pluripotent stem cells (iPSC) in the study of genetic heart diseases. 
 
The objective of this study was to confirm the quality of the iPS cell lines used in the 
Heart group for research purposes. The purpose of the study was to characterize six iPS 
cell lines qualitatively using immunocytochemistry, polymerase chain reaction, and 
microscopy. In addition to valid research, correct characterization aids the use and 
development of protocols. The cell lines characterized in this thesis are analyzed with 
respect to cell pluripotency and transgene expression. Other specifics, such as disease-
related mutations, are not assessed herein. 
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2 LITERATURE REVIEW 
 
 
2.1 Induced pluripotent stem cells 
 
 
2.1.1 Stem cell potency 
 
Stem cells are cells that are capable of proliferating extensively and differentiating 
towards several other cell types (Kolios & Moodley 2013). Depending on the 
differentiation capacity, stem cells are classified into different categories: totipotent, 
pluripotent, multipotent, and oligopotent stem cells (Mitalipov & Wolf 2009; Kolios & 
Moodley 2013). Zygotes are considered to be totipotent cells, giving rise to all cells, 
including pluripotent embryonic stem cells and extraembryonic tissues (Lovell-Badge 
2007; Mitalipov & Wolf 2009). Pluripotent stem cells are defined as cells capable of 
differentiating into any of the three germ lines and thus all adult cell types (Thomson et 
al. 1998; Mitalipov & Wolf 2009). Multipotent cells are derived from pluripotent cells 
and capable of differentiating into some cell types derived from a single germ layer, such 
as mesenchymal stem cells which form adipose tissue and bone, among others (Pittenger 
et al. 1999; Mitalipov 2009; Kolios & Moodley 2013). Oligopotent cells are considered 
tissue-resident progenitor cells with the potency to form a limited number of terminally 
differentiated cells (Kolios & Moodley 2010). Examples of oligopotent cells are 
lymphoid stem cells, forming B and T cells (Janeway et al. 2007, 15; Alberts et al. 2008, 
1457). It may be noted that oligopotent cells are not always defined as stem cells if a stem 
cell is considered a cell able to proliferate indefinitely (Seaberg & van der Kooy 2003). 
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2.1.2 Induction 
 
Cells resembling pluripotent embryonic cells (ESC) have previously been generated from 
somatic cells with two notable methods, nuclear transfer to oocytes, and fusion with ES 
cells (Yamanaka 2007). A breakthrough in reprogramming somatic cells came about 
when several studies displayed that fibroblasts from mouse and human are 
reprogrammable with defined factors, utilizing a viral vector (Maherali et al. 2007; Okita, 
Ichisaka & Yamanaka 2007; Takahashi et al. 2007; Wernig et al. 2007; Yu et al. 2007; 
Park et al. 2008). Subsequently, reprogramming has succeeded with multiple other cell 
types (Aoi et al. 2008; Hanna et al. 2008; Stadtfeld & Hochedlinger 2010). 
 
The induction of somatic cells into iPS cells is frequently carried out using four 
transcription factors, OCT3/4, SOX2, Klf4, and c-Myc, also referred to as the Yamanaka 
factors. Other combinations of factors have also been employed, including 1-4 factors in 
most cases. (Stadtfeld & Hochedlinger 2010.) All factors are not always required, but 
OCT3/4 and SOX2 are generally employed (Eminli et al. 2008; Rizzino 2009; Stadtfeld 
& Hochedlinger 2010). 
 
c-Myc is a factor occasionally replaced or left unused, as it is a known proto-oncogene 
and thus problematic with possible clinical applications when transduced with an 
integrating virus (Okita et al. 2007; Stadtfeld & Hochedlinger 2010). However, as it is 
shown that transgene integration into cell genome is not necessary for induced 
pluripotency, non-integrating methods have been devised to eliminate insertional 
mutagenesis (Okita et al. 2008; Varas et al. 2009). One of these methods exploits the use 
of non-integrating Sendai RNA virus (Fusaki et al. 2009). Other methods include the use 
of plasmids, episomes, reprogramming proteins, small molecules, and miRNA, among 
others (Huangfu et al. 2008; Yu et al. 2009; Grskovic et al. 2011; Miyazaki et al. 2012). 
Sometimes incomplete silencing or re-activation of transgenes occurs with retrovirally 
induced cells and may cause depencence on the transgene expression, tumorigenesis, and 
interference with development and differentiation (Stadtfelt & Hochedlinger 2010; 
Toivonen et al. 2013). Cell lines in this thesis have been produced with either retroviral 
or Sendai-viral induction (section 3.1.1). A schematic illustration of the proceduce is 
presented in figure 1. 
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FIGURE 1. Induction protocol. Phases: (1) The isolation and culture of somatic cells. (2) 
Transferring of reprogramming factors. (3) Harvesting the cells and culturing in 
pluripotent cell conditions (on a feeder layer). (4) The formation of iPS cell colonies. 
(Image: Y. Tambe 2007) 
 
When expressed in cells, the factors affect transcription, activating an expression network 
of several pluripotency-associated factors and series of events proceeding towards 
pluripotency (Kim et al. 2008; Wei et al. 2009). OCT3/4 and SOX2 are considered as 
core factors working synergistically, while c-Myc and Klf4 are thought to modify the 
chromatin structure for OCT3/4 and SOX2 binding (Takahashi 2007). In addition, c-Myc 
is proposed to universally amplify active gene expression, thereby enhancing the 
induction process (Nie et al. 2012). Obstacles that somatic cells must overcome in the 
course of reprogramming include the inhibition of somatic regulators, senescence and 
apoptotic pathways, the induction of proliferation, the activation of pluripotency loci, and 
independence from exogenous factor expression (Stadtfeld & Hochedlinger 2010). 
Endogenous factors expressed after induction are briefly addressed in section 2.2.2. 
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2.1.3 Applications 
 
iPS cells have prominent applications in cell and tissue modeling, drug discovery, gene 
repairing, and disease pathogenesis studies in vitro. In contrast to embryonic stem cells, 
iPS cells have the feature of being patient and disease-specific enabling the study of 
inherited conditions with iPS-cell derived cells and tissues without ethical concerns and 
limited availability surrounding embryonic cells and oocytes. Also, regenerative 
therapeutical applications could be conducted without the issue of tissue rejection. 
(Takahashi 2007; Yamanaka 2007; Stadtfelt & Hochedlinger 2010; Robinton & Daley 
2012.) Figure 2 shows a scheme describing the applications of iPSC. 
 
Human ES cells and iPS cells do not seem to exhibit significant differences in global gene 
expression patterns (Guenther et al. 2010). It is shown, however, that some iPS cells may 
retain a transient epigenetic memory especially in early passages (Kim et al. 2010). These 
differences with other concerns such as tumorigenesis need to be conclusively addressed 
before medical applications (Hyun et al. 2007). 
 
 
FIGURE 2. Applications for induced pluripotent stem cells. (Rodolfa 2008, modified) 
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2.2 Cell line characterization and pluripotency 
 
 
2.2.1 Profile of pluripotency 
 
The characterization of cells includes a set of defined tests to reach certainty on the cell 
type. iPS cells are frequently characterized with the criteria applied to ES cells (Ng & 
Choo 2010). As previously mentioned, there are some reported differences between iPS 
and ES cell characteristics considering expression patterns, but slight differences exist 
also between different iPSC and ESC lines. In the course of extended culture, however, 
iPS cells come to resemble ES cells probably due to the completion of reprogramming. 
(The International Stem Cell Initiative 2007; Ng & Choo 2010.) Features assessed by 
characterization include cell and colony morphology, growth rate, the expression of 
surface markers and other antigens, the expression of pluripotency marker genes, 
methylation statuses, enzyme levels, and differentiation into somatic cell types in vitro 
and in vivo (table 1). 
 
TABLE 1. Pluripotency indicating conditions frequently studied in cell line 
characterization protocols. (Takahashi et al. 2007; Ng & Choo 2010; Tiscornia et al. 
2011) 
Feature Status/marker/function 
Morphology Cells: high nucleus/cytoplasm ratio 
Colonies: round, tight, smooth borders 
Growth rate Comparable to ESC, Td ≈ 40-50 h. 
Surface marker proteins SSEA3, SSEA4, TRA 1-60, TRA 1-81, et al 
Undifferentiated ES markers Nanog, OCT3/4, REX1, SOX2, GDF3, FGF4, 
ESG1, DPPA2, hTERT, et al 
Unmethylated promoters of 
pluripotency-associated genes 
Nanog, OCT3/4, REX1, et al 
Enzyme levels Elevated telomerase levels 
Elevated alkaline phosphatase levels 
Embryoid bodies (in vitro diff.) Differentiation into the three germ layers 
Directed differentiation (in vitro) Differentiation into specified cell types 
Teratoma formation (in vivo diff.) Differentiation into the three germ layers 
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Among pluripotency markers, Nanog and OCT3/4 are regarded as archetypal pluripotent 
stem cell markers (The International Stem Cell Initiative 2007). In addition, it is noted 
that OCT3/4 and SOX2 work together through feedback loops regulating both their own 
transcription and other pluripotency-associated genes (Rizzino 2009). In this thesis, six 
antigens and five endogenous pluripotency marker genes are determined (table 2). The 
analysis of in vitro formed embryoid bodies is also carried out. Embryoid bodies are in 
vitro cell aggregates consisting of spontaneously differentiating cells (Kurosawa 2007). 
The target is to obtain cells from all three embryonic layers. 
 
TABLE 2. Gene and antigen markers analyzed. (Ben-Shushan et al. 1998; Shi et al. 2006; 
Schopperle & DeWolf 2007; The International Stem Cell Initiative 2007; Rizzino 2009; 
Theunissen & Silva 2011; Nie et al. 2012.) 
Marker Analyzed expression Role/type 
c-Myc Gene Expression amplifier, reinforcing the pluripotent 
state 
Nanog Gene, antigen Establishment of induced pluripotency, resisting 
differentiation 
OCT3/4 Gene, antigen Pluripotency maintentance and induction 
Rex1 Gene Transcription factor (zinc finger protein), 
regulated by OCT3/4, SOX2, & Nanog 
SOX2 Gene, antigen Pluripotency maintentance and induction 
SSEA4 Antigen Stage-specific embryonic antigen, cell surface 
glycolipid 
TRA 1-60 Antigen Stem cell surface keratan sulfate antigen epitope 
TRA 1-81 Antigen Stem cell surface keratan sulfate antigen epitope 
 
 
2.2.2 Factors maintaining pluripotency in cell culture 
 
Culturing conditions including culturing wells, media, incubator environment, and 
supportive matrices affect strongly the condition of the cell culture. Feeder cells are used 
frequently in cell culture. Feeders are cells secreting substances that support the cultured 
cells and provide a matrix to attach. They are rendered incapable of proliferation with 
chemical or physical means. 
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Mouse embryonic fibroblast (MEF) cells are commonly used in pluripotent stem cell 
cultures, where MEF feeder layer aids in the undifferentiated propagation of cells. 
Fibroblast feeders secrete a mixture of growth factors including transforming growth 
factor β (TGFβ), Activin A, Wnt proteins, BMP signaling antagonists, and some cell types 
also fibroblast growth factors (FGFs). Activin A is shown to induce OCT3/4 and Nanog, 
among others. FGF is essential for human embryonic stem cell self-renewal and has been 
shown to act in concert with pluripotency-maintaining signaling networks. FGF may be 
added into media as a supplement for maintaining stem cell pluripotency. (Vallier et al. 
2005; Levenstein et al. 2006; Eiselleova et al. 2008; Abraham et al. 2010, Rajala et al. 
2010; Pekkanen-Mattila et al. 2012.) 
 
To gain reproducible and reliable results and to maintain a stable cell culture over 
extended periods, several defined media and feeder-free culture systems have been 
suggested and experimented with. For instance, fetal bovine serum (FBS) has been in 
many cases replaced with serum replacements and feeder layers with gel and protein-
based systems. (Abraham et al. 2010, Rajala et al. 2010.) 
 
 
2.3 Methods for characterization 
 
 
2.3.1 RNA extraction 
 
Intact, high-quality, and high-yield RNA is required for many purposes in molecular bi-
ology. (Muyal et al. 2009; Vomelová et al. 2009). In this thesis, total RNA is isolated to 
study the expression of genes via the polymerase chain reaction of transcribed cDNA. 
There are three principal methods for RNA isolation: organic solvent (usually phenol-
chloroform) extraction, adsorption method, and isopycnic gradient separation (Muyal et 
al. 2009; Vomelová et al. 2009). 
 
Compared to large molecule DNA extraction, shorter RNA molecules tolerate more me-
chanical stress and can be isolated from cells with disruptive methods. However, RNA is 
susceptible to degradation by omnipresent ribonucleases and factors such as heat, ele-
vated pH, divalent cations, and extended storage periods. (Muyal et al. 2009; Wilson & 
Walker 2010, 165.) 
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Guanidinium isothiocyanate is a cationic detergent and a chaotropic salt which is used to 
lyse the sample and to denature endogenous ribonucleases. In the organic solvent method, 
the lysate is mixed usually with phenol-chloroform solution and centrifuged. Proteins 
precipitate between the phases. Upper phenolic phase containing nucleic acids is collected 
and RNA is precipitated with isopropanol, centrifuged and subsequently washed with 
ethanol. Deproteinisation can be carried out several times to ensure the purity of the RNA. 
(Muyal et al. 2009; Vomelová et al. 2009; Wilson & Walker 2010, 184-165.) 
 
The adsorption method is based on the interactions of RNA and an adsorptive matrix in 
the presence of a chaotropic salt. The adsorptive surface may be in the form of beads, 
coating, or a solid matrix. Materials used in these systems are i.a. silica, polystyrene-latex 
materials, cellulose, and glass fibres. Depending on the specific system used, the contam-
inants are washed or centrifuged away. (Vomelová et al. 2009.) This method is employed 
for extracting RNA in this thesis using a commercial silica-based spin column kit (Ma-
cherey-Nagel 2011). See figure 3 for illustration. 
 
In isopycnic gradient method, the sample is lysed as with other methods. The method is 
based on density differences between cellular components in a cesium salt solution. The 
solution is ultracentrifuged and the layer containing RNA is collected and precipitated. 
This method can be applied to isolate high purity RNA free of cellular components. 
(Vomelová et al. 2009; Wilson & Walker 2010, 164.) 
 
Previously described methods are used for total RNA extraction but methods exist to iso-
late e.g. only mRNA (Vomelová et al. 2009; Wilson & Walker 2010, 167). Today, the 
most widely used techniques are the phenol-chloroform extraction and the silica-gel col-
umn based method. The silica-gel column method has been demonstrated to isolate longer 
RNA fragments intact, although the total RNA yield may be higher with the phenol-chlo-
roform extraction. (Muyal et al. 2009.) 
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FIGURE 3. Silica-based spin column. (Image: Wikimedia Commons 2008) 
 
 
2.3.2 cDNA transcription 
 
To produce starting material for a polymerase chain reaction, isolated RNA has to be 
transcribed into complementary DNA (cDNA) (Alberts et al. 2008, 545). The transcrip-
tion is carried out with reverse transcriptase (RT) enzyme in a solution containing random 
primers and deoxynucleotides (Wilson & Walker 2010, 201). Reverse transcriptase pro-
duces single-stranded DNA molecules on an RNA template (Alberts et al. 2008, 542). 
 
 
2.3.3 Polymerase chain reaction 
 
Polymerase chain reaction (PCR) is a widely and commonly used method in molecular 
biology. It employs a thermostabile DNA polymerase enzyme, which amplifies any de-
sired DNA sequence in a chain reaction where the amount of the sequence doubles in 
each cycle. PCR is an extremely sensitive method, detecting minuscule amounts of target 
DNA. (Alberts et al. 2008, 545; Campbell & Farrell 2012, 377.) 
 
For the DNA polymerase to attach and begin synthesizing new DNA strands from deox-
ynucleotides (dNTPs), oligonucleotide primers are required. Primers are designed to com-
plementary bind to both strands of DNA, one primer for each strand, together bracketing 
the segment to be amplified. To design the primers, knowledge of the original sequence 
is required. (Alberts et al. 2008, 545; Wilson & Walker 2010, 179.) Figure 4 shows an 
illustration of primers with DNA strands. 
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FIGURE 4. Primers showing complementarity with DNA strands. (Image: Wheeler 2013) 
 
 
PCR includes three main phases. First, the reaction mixture is heated to denature the 
DNA and separate the two strands. Second, the temperature is lowered sufficiently for 
the primers to anneal to the strands. Third, the temperature is raised to optimize the ac-
tivity of the DNA polymerase and begin the extension, or elongation, of strands. These 
three phases are repeated for multiple cycles, e.g. 20-30. (Alberts et al. 2008, 544; Wilson 
& Walker 2010, 181; Campbell & Farrell 2012, 377.) The phases are depicted in figure 
5. PCR reactions are carried out in tubes inside a programmable thermocycler. Annealing 
temperature is calculated for each primer-pair according to its properties (Campbell & 
Farrell 2012, 377). 
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FIGURE 5. PCR phases. (Image: Ball 2007) 
 
Reaction products can be visualized after the separation with gel electrophoresis. Running 
the DNA sample into an agarose gel using direct electric current separates DNA frag-
ments, as larger fragments take more time to migrate through the pores in the gel matrix. 
DNA is frequently visualized using ethidium bromide as a component in the gel. Ethidium 
bromide intercalates between the stacked nucleotide base pairs and fluoresces when illu-
minated with UV light. (Watson et al. 2004, 648; Wilson & Walker 2010, 168.) 
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2.3.4 Immunofluorescence staining 
 
Antibodies, also known as immunoglobulins, are proteins produced by plasma cells that 
bind specifically to particular substances referred to as antigens (Eales 2003, 41; Janeway 
et al. 2007, 824). Antibodies share the same fundamental structure (figure 6) (Wilson & 
Walker 2010, 270). Antibodies are utilized in biosciences to identify specific molecules 
in biological matrices. 
 
 
FIGURE 6. Simplified presentation of a Y-shaped antibody. (Image: Wikimedia Com-
mons 2007) 
 
Immunofluorescence staining refers to immunochemical methods based on the use of flu-
orescent dyes attached to antibodies. The location of the antigens in a sample is ascer-
tained when the sample is illuminated with a dye-specific excitatory wavelength. Fluo-
rescent label may be directly attached to the antibody or indirectly to a secondary antibody 
which, in turn, binds to the primary antibody. (Janeway et al. 2007, 735-737.) An indirect 
method is elucidated in figure 7. 
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A matter that is taken into account when using fluorescent dyes is a phenomenon called 
photobleaching, denoting damage to the dye when overexcited with light (Bernas et al. 
2004; Wilson & Walker 2010, 116). Photobleaching is prevented with adequate staining 
practices, such as a dim environment and foil shielding. Anti-fading agents are also fre-
quently included in mounting media for stained specimens (Longin et al. 1993; Ono et al. 
2001). 
 
In addition to staining the target molecules, common cell structures are frequently coun-
terstained to obtain a more comprehensive view and vivid photographs. A common coun-
terstain for cells is DAPI (4'-6-diamidine-2-phenyl indole), which stains DNA by inser-
tion inside the helix (Larsen et al. 1989). 
 
 
 
FIGURE 7. Indirect immunofluorescence staining. (Image: Munch 2007) 
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3 MATERIALS AND METHODS 
 
 
3.1 Cell culture 
 
 
3.1.1 Origin of the cells 
 
The five human iPS cell lines characterized in this thesis had been produced from 
fibroblast cells obtained from skin biopsies. Skin biopsies had been taken from cardiac 
patients carrying a certain type of abnormality in their genome predisposing them to heart 
disease. A control cell line (wildtype) used had been produced from blood cells of a 
healthy individual. Cell lines are listed in table 3 with the induction method used. 
Abbreviations used in the names of the cell lines are explained in table 4. 
 
TABLE 3. Cell lines. 
Cell line Induction method 
UTA.07001.CPVT Retrovirus 
UTA.05303.CPVT Retrovirus 
UTA.05404.CPVT Retrovirus 
UTA.01402.HCMTs Sendai virus 
UTA.02912.HCMTs Sendai virus 
UTA.11505.WTsb Sendai virus 
 
 
TABLE 4. Abbreviations in cell line designations. Latter capitalized letters indicate the 
disease-related genotype and lowercase letters technicalities. 
Abbreviation Explanation / disease genotype 
UTA University of Tampere 
CPVT Catecholaminergic polymorphic ventricular tachycardia 
HCM Hypertrophic cardiomyopathy 
WT Wildtype 
s Sendai-viral induction 
b Blood cell-derived 
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3.1.2 Culture conditions 
 
The cell cultures were maintained in a cell culture laboratory under aseptic conditions. 
The culturing plates were kept in an incubator set to 37 °C temperature. The temperature 
was monitored on a daily basis. The carbon dioxide levels in the incubator were set to 
5.0% for controlling the medium pH (Chakrabarti & Chakrabarti 2001). The incubator 
was humidified by keeping sterile water on a tray inside the incubator. 
 
The cells were cultured on regular plastic 6-well plates with gelatin coating and mouse 
embryonic fibroblast (MEF) feeder layer (see section 3.1.3). KSR medium was used to 
support cell growth. KSR medium is a serum free, KnockOut™ Serum Replacement 
(KO-SR) based cell culture medium (contents in appendix 1). Before use, KSR medium 
was supplemented with fibroblast growth factor (bFGF). The morphology of the cell 
colonies was assessed visually and colonies were photographed with an inverted phase 
contrast microscope system (see figures 8 & 9, section 4.1). 
 
 
3.1.3 Passaging 
 
The cell lines were enzymatically passaged once a week to prevent the colonies from 
overgrowing. For the passaging, a MEF feeder layer was prepared on the wells. Passage 
numbers were used to follow the approximate age of the cultures, one unit standing for 
approximately one week. 
 
First, the wells were coated with gelatin. The coating was prepared by applying 1 ml of 
autoclave sterilized 0.1% gelatin (porcine, type A) in dH2O onto the wells and letting 
gelatin bind for an hour at room temperature. After binding, excess gelatin was aspirated. 
Mitotically inactivated MEF cells were stored in gas phase liquid nitrogen storage 
(Millipore™ EmbryoMax® PMEF P3 Strain CF-1 MitoC treated). The MEF cell vials 
containing 5 million cells per vial were thawed in 37 °C water bath. Pre-warmed MEF 
medium was carefully added into the thawed ampoule to reduce osmotic shock (for MEF 
medium contents, see appendix 1). The suspension was then transferred into a 50 ml tube 
of pre-warmed MEF medium and carefully mixed. Cell suspension was transferred into 
the gelatin-coated wells adding 2.5 ml of suspension per well. The plates were kept in an 
incubator overnight to let the MEF cells attach. 
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On the following day, the MEF medium was aspirated from the wells and replaced with   
pre-warmed KSR+FGF medium, 1.5 ml/well. From the iPSC wells to be passaged, the 
MEF layer and inferior colonies were detached using sterile pipette tips. The medium 
with detached material was aspirated from the wells. 1 ml of 1 mg/ml collagenase IV 
solution was added onto the wells and incubated for 5 minutes at room temperature. The 
collagenase solution was then aspirated and a sufficient amount of KSR+FGF medium 
was added. Cell colonies were carefully detached by pipetting and transferred within the 
medium into new wells. 
 
Some of the cells were occasionally frozen for storage purposes. Before freezing, the 
feeder layer was removed and aspirated, the cell colonies were scraped off with a sterile 
instrument and cell colony suspension was centrifuged at 300 G for 5 minutes. 
Supernatant was aspirated and freezing medium (appendix 1) was added, 0.5 ml/vial. Cell 
suspension was transferred into cryovials. 0.5 µl of ROCK-inhibitor was added into each 
vial to aid cell survival (Claassen et al. 2009). Subsequently, the vials were transferred 
inside a cooling container into a -80 °C freezer and next day into gas phase liquid nitrogen 
storage. The thawing of the cells was carried out in the same fashion as with the MEF 
cells. 
 
 
3.1.4 Embryoid body culture 
 
For embryoid body culture, the cells were passaged from regular 6-well plates into low-
attachment 12-well plates with no feeder layer or gelatin coating. 2 wells from 6-well 
plate were split to 4 wells on 12-well plates. The culturing medium was embryoid body 
medium with no FGF and a higher concentration of KO-SR compared to KSR medium 
(appendix 1). The medium was changed completely once a week for the 5-week growing 
period. The cells were incubated in the same environment as the iPS cells. 
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3.2 Characterization of cell lines 
 
 
3.2.1 Obtaining cDNA 
 
RNA extraction with spin column method 
RNA extraction from the cells was carried out using Macherey-Nagel NucleoSpin® RNA 
II kit. The kit is a spin column system based on a silica matrix and extraction in the 
presence of guanidinium thiocyanate-containing buffer (Macherey-Nagel 2011). Cell 
samples were obtained from a single 6-well plate culturing well each. Prior to taking the 
sample, the cells were washed two times with PBS. Detached cell suspension was 
centrifuged, PBS was aspirated and 350 µl of RA1 buffer including 3.5 µl of β-
mercaptoethanol was added. Applying the buffer lysed the cells and the samples were 
stored at -80 °C before the extraction. 
 
The thawed sample was first centrifuged through NucleoSpin filter to clear the lysate. 
Ethanol was then added to the filtrated lysate to adjust RNA binding conditions. The mix 
was then loaded to NucleoSpin RNA II column and centrifuged. Membrane desalting 
buffer was added onto the filter and centrifuged to enhance the following rDNase 
digestion. RDNase solution was applied onto the filter for a 15 minute incubation at room 
temperature. RA2 buffer was added to the column and centrifuged to inactivate the 
rDNase. The column was then washed two times with RA3 buffer and centrifuged after 
the washes. Finally, RNA was eluted into a sterile collection tube with RNase-free water. 
(Macherey-Nagel 2011.) The procedure was carried out for each sample. The protocol is 
summarised in table 5. 
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TABLE 5. Total RNA isolation protocol for NucleoSpin® RNA II kit. (Macherey-Nagel 
2011) 
Phase Reagent Centrifugation at 
11 000 g 
Lyse cells 350 μL RA1 + 3.5 μL β-
mercaptoethanol 
 
Filtrate lysate NucleoSpin filter 1 min 
Adjust RNA binding conditions 350 µl 70 % ethanol  
Bind RNA NucleoSpin RNA II column 30 s 
Desalt silica membrane 350 µl MDB 1 min 
Digest DNA 95 µl rDNase mix (10 % 
rDNase stock in H2O) 
incubation at RT 
for 15 min 
Wash and dry silica membrane 1st wash: 200 µl RA2 30 s 
 2nd wash: 600 µl RA3 30 s 
 3rd wash: 250 µl RA3 2 min 
Elute RNA RNase-free H2O (supplied) 1 min 
 
NanoDrop spectrophotometer was used to measure the concentration and purity of the 
RNA extracts. The results of the measurements are listed in table 6. Prior to the usage, 
RNA samples were stored at -80 °C. New cultured samples were taken from lines 
UTA.07001.CPVT and UTA.05404.CPVT due to the problems later encountered with 
PCR. 
 
TABLE 6. RNA concentrations, purity and volume for cDNA transcription. 
Sample cell line Passage RNA 
concentration 
RNA purity 
(A260/A280) 
Volume for 
transcription 
UTA.07001.CPVT 15 13.3 ng/µl 2.26 10 µl 
UTA.05303.CPVT 13 133.4 ng/µl 2.13 7.50 µl 
UTA.05404.CPVT 19 74.41 ng/µl 1.91 10 µl 
UTA.01402.HCMTs 10 53.28 ng/µl 2.20 10 µl 
UTA.02912.HCMTs 14 109.6 ng/µl 2.17 9.12 
UTA.11505.WTsb 29 98.33 ng/µl 2.15 10 µl 
UTA.07001.CPVT (new) 27 42.18 ng/µl 2.18 10 µl 
UTA.05404.CPVT (new) 31 119.9 ng/µl 2.16 8.34 µl 
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cDNA transcription 
cDNA transcription was carried out using Applied Biosystems’ High Capacity cDNA 
Reverse Transcription kit. The master mix was prepared for the reverse transcription 
reactions according to table 7. 10 µl of the master mix was added to PCR tubes for each 
reaction. The amount of RNA for each reaction was determined to be the maximum from 
each cell line but ≤ 1000 ng, since all samples did not yield to 100 ng/µl concentration 
required for 1000 ng amount. The volume of each extract was calculated accordingly 
(table 6). The total reaction volume was 20 µl. A control sample was prepared with 
reverse transcriptase replaced with H2O. The temperature program for the thermocycler 
is in table 8. 
 
TABLE 7. Master mix components for reverse transcription in one reaction. 
Reagent µl 
10x RT buffer 2.0 
25x dNTP mix (100 µM) 0.8 
10x RT random primers 2.0 
MultiScribe™ Reverse Transcriptase 1.0 
RNase inhibitor 0.5 
Nuclease-free H2O 3.7 
Total volume 10 
 
 
TABLE 8. Temperature program for cDNA transcription.  
Step Temperature Time 
#1 25 °C 10 min 
#2 37 °C 120 min 
#3 85 °C 5 min 
#4 4 °C hold 
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3.2.2 Analysis of exogenous genes 
 
To study the expression status of viral exogenes, previously transcribed cDNA was used 
for the PCR protocol. Master mixes were aseptically prepared for the reactions into 
Eppendorf tubes according to table 9. The DNA polymerase was from Thermo Scientific. 
In PCR, dimethyl sulfoxide (DMSO) disrupts base pairing and strand re-annealing and is 
used with some primers to prevent the formation of secondary structures especially in GC 
rich areas (Baskaran et al. 1996; Mammedov et al. 2008; Jensen et al. 2010). Primers used 
were designed to attach to the viral transgene OCT3/4, SOX2, Klf4, and c-Myc cDNA. A 
housekeeping gene, GAPDH, was used as a control. GAPDH, producing glyceraldehyde-
3-phosphate dehydrogenase, is a maintenance gene and known to be perpetually 
expressed in cells to a degree (Warrington et al. 2000; Barber et al. 2005).  
 
TABLE 9. Master mix components for one reaction in the analysis of exogenous genes. 
Reagent µl 
10x buffer (DyNAzyme™) 2,5 
dNTP mix (10 mM) 0,5 
primer F (5 uM) 2,5 
primer R (5 uM) 2,5 
DNA Polymerase (DyNAzyme™ II) 0,25 
MgCl (25 mM) 0,5 
DMSO (not for GAPDH master mix) 1,25 
H2O 14 (15,25) 
Total volume 24 
 
 
The total volume of 24 µl of the master mix was used for each reaction. The master mixes 
were pipetted into PCR tube strips and 1 µl of the sample cDNA solutions were added. 
Transgene plasmid solutions were used as positive control samples. Three blank samples 
were used to check possible contamination: water from cDNA transcription and PCR 
master mixes and –RT sample from cDNA transcription. Reaction tubes were mixed by 
tapping and spun in a microcentrifuge. A standard temperature program was used for the 
reactions with 40 cycles and the annealing temperature of 55 °C (table 10). 
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TABLE 10. Temperature program for PCR cycler in the analysis of exogenous genes. 
Step Temperature Time  
#1 94 °C 2 min  
#2 94 °C 30 s  
#3 55 °C 30 s      40 cycles 
#4 72 °C 1 min  
#5 72 °C 5 min  
#6 4 °C hold  
 
 
A 2% w/v agarose gel was used to analyze the results. Ethidium bromide was used as a 
fluorescent DNA label. The gel was prepared by weighing 3 g of agarose and mixing it 
with 150 ml of TRIS-borate-EDTA (TBE) buffer solution. The suspension was brought 
to a boil and re-heated in a microwave oven so that the agarose was completely dissolved. 
3.75 µl of 10 mg/ml ethidium bromide was added and mixed into the sufficiently cooled 
solution. Gel was poured into a tray to polymerize for 45 min at room temperature. The 
samples were mixed with 4.2 µl of 6x DNA loading dye (Thermo Scientific). 50 bp DNA 
ladder was used as a size standard. The gel was immersed in TBE and the samples were 
loaded into the wells. Electrophoresis was ran for 1 hour with a voltage of 80 V. The gel 
was photographed in UV light. For the results, see section 4.2. 
 
 
3.2.3 Analysis of endogenous pluripotency genes 
 
To study the expression of endogenous pluripotency marker transcription factors, a PCR 
protocol was carried out using the previously transcribed cDNA. Five analyzed factors 
were Nanog, Rex1, OCT3/4, SOX2, and c-Myc. GAPDH was used as a control as 
previously. The protocol was conducted as with transgene analyses, with the exception 
of using temperature gradient to perform several reactions with differing annealing 
temperatures concurrently. The master mix components for the reactions are listed in table 
11 and thermocycler temperature program in table 12. The gel photographs can be found 
in section 4.3. 
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TABLE 11. Master mix components for one reaction in the analysis of endogenous genes. 
Reagent µl 
10x buffer (DyNAzyme™) 2,5 
dNTP mix (10 mM) 0,5 
primer F (5 uM) 2,5 
primer R (5 uM) 2,5 
DNA Polymerase (DyNAzyme™ II) 0,25 
MgCl (25 mM) 0,5 
DMSO (for Nanog master mix) 1,25 
H2O 15,25  (14) 
Total volume 24 
 
 
TABLE 12. Temperature program for PCR cycler in the analysis of endogenous genes. 
Step Temperature Primers Time  
#1 94 °C  2 min  
#2 94 °C  30 s  
 45 °C Nanog        
#3 55 °C GAPDH, Rex1 30 s      40 cycles 
 60 °C OCT3/4, SOX2, c-Myc   
#4 72 °C  1 min  
#5 72 °C  5 min  
#6 4 °C  hold  
 
 
3.2.4 Analysis of embryoid bodies 
 
After 5 weeks of culture, embryoid body samples were collected, RNA was extracted and 
cDNA transcribed as previously described with the iPS cells. RNA properties and 
volumes for cDNA transcription are listed in table 13. Six genes, two from each layer, 
were chosen for the subsequent PCR analysis (table 14). The master mix composition and 
temperature program were equivalent with the analyses of exogenous genes (tables 9 and 
10). Agarose gel electrophoresis was carried out for the products, the results are in section 
4.4. 
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TABLE 13. RNA concentrations and purity in embryoid body samples. 
Sample cell line Passage RNA concentration, 
ng/µl 
RNA purity 
(A260/A280) 
Volume for 
transcription, µl 
UTA.07001.CPVT 15 51.27 2.21 10 
UTA.05303.CPVT 11 117.1 2.21 8.54 
UTA.05404.CPVT 18 34.67 2.15 10 
UTA.02912.HCMTs 13 100.8 2.19 9.92 
UTA.01402.HCMTs 10 296.0 2.16 3.38 
UTA.11505.WTsb 33 102.6 2.22 9.75 
 
 
TABLE 14. Analyzed embryoid body related genes and respective germ layers. 
Gene Related germ layer 
SOX17 Endoderm  (Niakan et al. 2010; Wang et al. 2011) 
AFP Endoderm  (Schroeder et al. 2012; Rajala et al. 2010) 
Nestin Ectoderm   (Jagtap et al. 2011) 
PAX6 Ectoderm   (Surmacz et al. 2012) 
α-cardiac actinin Mesoderm  (Poudel et al. 2011) 
VEGFR2/KDR Mesoderm  (Takenaga et al. 2007) 
 
 
3.2.5 Immunofluorescence staining 
 
For immunofluorescence staining, the cell lines were split for culturing on 12-well plates, 
each plate containing one cell line. The cells were cultured on seven wells, one well for 
each of the six antibodies and a secondary antibody control well. Before splitting, the 
wells were gelatin coated and plated with mouse embryonic fibroblast feeder cells as 
previously described. 
 
KSR+FGF medium was changed for the cells in 2-3 day intervals as described previously. 
After 5-7 days of culture, the culturing medium was removed and the cells were fixed 
(see table 15). Before fixing, the cells were washed two times with PBS for five minutes 
a wash. Fixing was carried out applying 350 µl of 4 % w/v paraformaldehyde (PFA) 
solution into wells empty of liquid. The plates were incubated for 20 minutes at ambient 
temperature and subsequently washed two times with PBS as previously. 
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The fixed plates were stored at +4 °C in a cold storage room for varying periods of time, 
maximum time being two months. The passage data are listed in appendix 2.  
 
Before treating the cells with primary antibodies, the wells were treated with blocking 
solution to reduce non-specific antibody binding (Kenna et al. 1985). Blocking was 
carried out applying normal donkey serum (NDS) based blocking solution to wells 
following an incubation of 45 minutes at ambient temperature (see table 15 & appendix 
2). Blocking solution was aspirated and wells were washed once with primary+washing 
solution. 
 
2 mg/ml primary antibody solutions were diluted with appropriate amounts of 
primary+washing solution to achieve desired dilutions. Onto each well, 750 µl of 
appropriate antibody solution was applied. Only primary+washing solution without the 
antibody was added to the control wells. The plates were incubated overnight at +4 °C. 
For the list of primary antibodies used, see table 16. 
 
After incubation, the wells were washed three times with PBS for five minutes a wash. 
Secondary antibody solutions (2 mg/ml) were prepared by diluting antibody stock 
solutions with secondary+washing solution (appendix 2). Secondary antibody solutions 
were applied and incubated for one hour, protected from light. Secondary antibodies used 
were labeled with Alexa Fluor® 568, a sulfonated derivative of rhodamine (Panchuk-
Voloshina et al. 1999) (table 17). 
 
The wells were subsequently washed two times with PBS and then two times with PB 
(phosphate buffer), 5 minutes a wash. The wells were emptied of liquid. 1-2 drops of 
Vectashield® (Vector Laboratories) mounting solution with DAPI counterstain was 
added onto the wells. Finally, cover glasses were added. The stained plates were stored 
in a cold storage room at +4 °C, protected from light. 
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TABLE 15. Fluorescence staining protocol. 
Step Volume / well Incubation at RT 
Washing with PBS 2 x 1 ml 5 min / wash 
Fixing with 4 % PFA 350 µl 20 min 
Washing with PBS 2 x 1 ml 5 min / wash 
Blocking 0.7 ml 45 min 
Washing with primary+washing solution 1 ml - 
Applying primary antibodies 750 µl overnight at +4 °C 
Washing with secondary+washing solution 3 x 1 ml 5 min / wash 
Applying secondary antibodies 750 µl 60 min, dark 
Washing with PBS 2 x 1 ml 5 min / wash, dark 
Washing with PB 2 x 1 ml 5 min / wash, dark 
Mounting with Vectashield® 1-2 drops - 
 
 
TABLE 16. List of primary antibodies. 
Antibody Dilution Vendor 
Anti-human Nanog goat IgG 1:100 R&D Systems® 
Anti-human OCT 3/4 goat IgG 1:400 R&D Systems® 
Anti-human SSEA4 mouse IgG 1:100 Santa Cruz 
Anti-human SOX2 goat IgG 1:200 Santa Cruz 
Anti-human TRA-1-60 mouse IgM 1:200 Millipore™ 
Anti-human TRA-1-81 mouse IgM 1:200 Millipore™ 
 
 
TABLE 17. List of secondary antibodies. 
Antibody Dilution Vendor 
Alexa Fluor® 568 donkey anti-goat IgG (H+L) 1:800 Life Technologies™ 
Alexa Fluor® 568 goat anti-mouse IgG (H+L) 1:800 Life Technologies™ 
Alexa Fluor® 568 goat anti-mouse IgM (µ chain) 1:800 Life Technologies™ 
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The stained cells were photographed with a fluorescence microscope (Olympus IX51®) 
using 320 nm filter for DAPI and 560 nm filter for Alexa Fluor® 568 labels. Absorption 
maximum for Alexa Fluor® 568 dye is reported to be 578 nm and emission maximum 
603 nm (Life Technologies 2013). For DAPI, these wavelengths are 347 nm and 448 nm, 
respectively (Kapuscinski 1990). Photographs were taken as grayscale and coloured with 
an image processing program. Red colour was used for the antibody and blue colour for 
DNA (DAPI). For the results, see section 4.5. 
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4 RESULTS 
 
 
4.1 Morphology 
 
The morphology of the iPS cell colonies was evaluated after days 2 and 6 after the previ-
ous passaging. Photographs are presented in figures 8 and 9. All of the photographs show 
a clear growth in colony sizes in four days indicating exponential proliferation. Doubling 
time was not determined for the cells. The cells exhibit small, round features in contrast 
to surrounding fibroblast feeder cells. 
 
  
  
  
FIGURE 8. On the left: 2 days after the passaging, on the right: 6 days after the passaging. 
(A)&(B) UTA.07001.CPVT, (C)&(D) UTA.05303.CPVT, (E)&(F) UTA.05404.CPVT. 
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FIGURE 9. On the left: 2 days after the passaging, on the right: 6 days after the passaging. 
(A)&(B) UTA.02912.HCMTs, (C)&(D) UTA.01401.HCMTs, (E)&(F) 
UTA.11505.WTsb. 
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4.2 Exogenous genes 
 
EtBr-labeled agarose gels were photographed using a UV-cabinet. Printed results are pre-
sented in figure 10. Photographs include 50-5000 bp standard DNA ladder with 50 bp 
intervals and brighter bands at 250 and 500 bp for approximate size determination. Ex-
pected nominal band sizes are listed in table 18. The results show without controversy 
that all transgenes were unexpressed. Positive controls and GAPDH are visible in each 
line (figure 10, A-D). In addition to the cell lines and genes labelled, a comprehensive 
chart including passage data is included in appendix 3. Cell line UTA.01401.HCMTs was 
an additional line not included in the thesis. 
 
      500 & 250bp 
 
       GAPDH           c-Myc                    Klf4 
 
 
 
         SOX2                 OCT3/4               blank    
                                            
 
        OCT3/4                Klf4                 GAPDH 
 
 
         SOX2                  c-Myc                 blank 
 
FIGURE 10. PCR results for exogenous genes. Samples are grouped by genes. On the 
left, 50-1000 bp ladder with 50 bp intervals with brighter bands at 250 and 500 bp. 
(A) & (B) Band 1: UTA.07001.CPVT, band 2: UTA.05303.CPVT, band 3: 
UTA.05404.CPVT, band 4: positive control. (C) & (D) Band 1: UTA.02912.HCMTs, 
band 2: UTA.01401.HCMTs, band 3: UTA.01402.HCMTs, band 4: UTA.11505.WTsb, 
band 5: positive control. 
TABLE 18. Transgene-related fragment sizes in base pairs. 
retro exo OCT3/4 200-250 
retro exo SOX2 >200 
retro exo Klf4 250-300 
retro exo c-Myc <400 
Sendai exo OCT3/4 483 
Sendai exo SOX2 451 
Sendai exo Klf4 410 
Sendai exo c-Myc 532 
GAPDH 302 
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4.3 Endogenous pluripotency genes 
 
Gel photographs were obtained as previously described. Expected nominal band sizes are 
listed in table 19. The results presented here considering lines UTA.07001.CPVT and 
UTA.05404.CPVT have been obtained with the new samples (table 6). With the excep-
tion of c-Myc, all endogenous markers were expressed (figure 11). In two lines, OCT3/4 
expression was not observed (figure 11 (B)), so the analysis was repeated and expression 
then confirmed (figure 11 (D)). c-Myc exhibited weak expression in two lines. Table 20 
summarizes the observed gene expression. In addition to cell lines and genes labelled, a 
comprehensive chart including the passage data is included in appendix 3. 
 
 
      07001.CPVT        05404.CPVT          blank 
 
 
        11505.WTsb         05303.CPVT         blank 
 
     02912.HCMTs       01402.HCMTs       blank 
 
 
11505.WTsb  05303.CPVT    blank 
 
FIGURE 11. Endogenous pluripotency marker PCR results. Samples are grouped by cell 
lines. The order of genes in each series of bands from left to right: 1. Nanog, 2. GAPDH, 
3. Rex1, 4. OCT3/4, 5. SOX2, 6. c-Myc (except UTA.07001.CPVT: 2. OCT3/4, 3. SOX2, 
4. GAPDH, 5. Rex1). Supplementary bands in (D): 1. β-actin, 2. OCT3/4. 
 
TABLE 19. Fragment sizes in base pairs. 
 
 
 
 
 
 
 
 
 
 
 
Endo Nanog 287 
Endo OCT3/4 144 
Endo Rex1 306 
Endo SOX2 151 
Endo c-Myc 328 
GAPDH 302 
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TABLE 20. The observed expression of endogenous pluripotency markers in cell lines. 
Markings: + expression, - no expression, w: weak expression. 
 Nanog GAPDH Rex1 OCT3/4 SOX2 c-Myc 
UTA.07001.CPVT + + + + + - 
UTA.05303.CPVT + + + + + - 
UTA.05404.CPVT + + + + + w 
UTA.01402.HCMTs + + + + + - 
UTA.02912.HCMTs + + + + + - 
UTA.11505.WTsb + + + + + w 
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4.4 Embryonic layer genes in embryoid bodies 
 
Gel photographs were obtained as previously described. Expected nominal band sizes are 
listed in table 21. All lines exhibited the three embryonic layers with at least one gene per 
germ layer (figure 12, table 22). Two lines, UTA.07001.CPVT and UTA.01402.HCMTs 
expressed all studied genes including housekeeping gene GAPDH. In addition, two lines, 
UTA.05303.CPVT and UTA.11505.WTsb, failed to express GAPDH. AFP produced two 
different-sized bands, most evident in figure 12 (D). Table 22 summarizes the observed 
gene expression. In addition to the cell lines and genes labelled, a comprehensive chart 
including the passage data is included in appendix 3. 
 
 
                                 07001.CPVT             blank 
 
 
         05303.CPVT              blank 
 
 
                                 05404.CPVT 
 
 
          11505.WTsb 
 
 
                                  02912.HCMTs 
 
          01402.HCMTs           blank 
 
FIGURE 12. Embryonic germ layer marker PCR results. Samples are grouped by cell 
lines. The order of genes in each series of bands from left to right: 1. SOX17, 2. α-cardiac 
actinin, 3. Nestin, 4. AFP, 5. PAX6, 6. GAPDH, 7. VEGFR2/KDR. 
 
TABLE 21. EB-related PCR fragment sizes in base pairs. 
 
 
 
 
 
 
 
 
EB SOX17 120 bp 
EB α-cardiac actin 486 bp 
EB Nestin 208 bp 
EB AFP 672 bp 
EB PAX6 274 bp 
EB VEGFR2/KDR 218 bp 
GAPDH 302 bp 
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TABLE 22. Observed gene expression in embryoid body samples. Markings: + expres-
sion, - no expression, w: weak expression. 
 SOX17 α-actinin Nestin AFP PAX6 GAPDH VEGFR2 
Embryonic layer 
(-derm) 
endo meso ecto endo ecto control meso 
UTA.07001.CPVT + + + + + + + 
UTA.05303.CPVT - - + + - - + 
UTA.05404.CPVT + w + + - + + 
UTA.01402.HCMTs + + + + + + + 
UTA.02912.HCMTs w - + + + + + 
UTA.11505.WTsb w - + + - - + 
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4.5 Immunofluorescence staining 
 
All of the six cell lines were succesfully stained. Protein expression was observed with 
all six antibodies in all lines. None of the three fluorescent labeled secondary antibodies 
caused observable background staining or noise. There was no notable autofluorescence 
effects. Staining intensities differed both between cell lines and antibodies. Figure 13 
shows one staining result of each antigen and figure 14 the three secondary antibody 
control stainings. 
 
  
  
  
FIGURE 13. Immunofluorescence staining for pluripotency markers. Red color indicates 
antigen, blue DNA. (A) Nanog, (B) OCT3/4, (C) SSEA4, (D) SOX2, (E) TRA 1-60, (F) 
TRA 1-81. 
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FIGURE 14. Secondary antibody control stainings. Red color indicates antigen, blue 
DNA. (A) Anti-goat IgG, (B) Anti-mouse IgG, (C) Anti-mouse IgM. 
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5 DISCUSSION 
 
 
The morphology of iPS cell colonies was expected, exhibiting charasteristics of human 
pluripotent stem cells, such as high nucleus-to-cytoplasm ratio, dense, flat, colonies and 
smooth colony borders. The characteristics differ notably from other cells, such as 
parental human dermal and mouse embryonic fibroblasts. Similar morphology has been 
described with other iPS cells in several studies. (Takahashi et al. 2007; Yu et al. 2009; 
Okita et al. 2011.) 
 
The analyses of viral transgene expression were performed for cultures with passage 
number ranging from 10 to 29. The analyses exhibited no evidence of transgene 
expression, whether residual or due to reactivation. Transgenes are thus silenced in both 
the integrating retroviral-derived and non-integrating Sendai-viral-derived cell lines 
studied. Of the five endogenous factors analyzed, all but c-Myc were expressed, most 
importantly the key pluripotency factors OCT3/4 and Nanog. c-Myc is considered of 
value in reprogramming, but not necessarily as a pluripotency marker (Takahashi et al. 
2007). All embryoid body samples analyzed included at least one marker for each of the 
three germ layers, thus presenting in vitro preliminary potential to differentiate into all 
adult cells. Embryoid bodies from cell line UTA.02912.HCMTs were accidentally 
cultured on regular plates rather than on low-attachement plates but it had apparently no 
effect on differentiation (figure 12, (E)). Passage numbers of lines used in endogenous 
marker studies ranged from 10 to 31 and in embryoid body culture from 10 to 33. 
Expression does not seem to have correlated with passage numbers. Passage range is not 
broad and the amount of data is insufficient for general implications. 
 
The data from the immunofluorescence stainings support positive results for Nanog, 
OCT3/4 and SOX2. In addition, all other pluripotency markers were observed in all cell 
lines. The passage number of a line or date of fixation surprisingly did not correlate with 
the staining results in terms of colour intensity. Additionally, the colour intensity could 
not be realibly correlated with any specific practice or parameter and may be attributed 
to different amount of antigens in the samples. Antibody binding could also vary in 
samples due to differing pH values. Several washing steps should however have 
eliminated this possibility. Intensity differences may also arise from photobleaching. 
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RNA purity ratios ranged from 1,91 to 2,26 in iPS cell samples and from 2,15 to 2,22 in 
embryoid body samples. RNA is considered to be pure around ratio 2,0 and contaminated 
with protein or DNA below 1,8 (Vomelová et al. 2009; Wilson & Walker 2010, 167). The 
measured purities can be considered satisfactory. The originally contemplated 
comparison between low and high RNA concentration for the cDNA transcription and 
the subsequent PCR was discarded, since several samples yielded only low amounts of 
RNA. Advice from the kit manufacturer for better yields included pre-heating the elution 
water to 37-50 °C, incubating the elution water 5 minutes prior to the centrifugation, and 
repeating the elution with the once-through eluate. These notes should be taken into 
practice in the future while also pursuing to use samples with high cell count. 
 
Double banding was shown with endoderm-related gene AFP and mesoderm-related α-
cardiac actinin in embryoid body PCR analyses (see figure 12). Two separate gel bands 
may have occurred if template DNA has formed secondary structures such as coiled DNA 
in addition to desired linear structure. Again, this might be caused by improper buffer 
conditions or the tendency of the specific DNA sequence to form secondary structures, 
which allows DNA polymerase to amplify partly only free uncoiled sequences. This 
might be resolved with use of additional reagents, such as DMSO and betaine. (Kang et 
al. 2005; Mammedov et al. 2008.) 
 
β-actin was used in place of GAPDH as a housekeeping gene control in one PCR reaction 
(figure 11, (D)) since GAPDH was for unknown reason not functioning properly. It has 
been argumented over if GAPDH is a suitable housekeeping gene for different PCR 
analyses and noted that notable differences in expression levels exist between tissue types 
and some differences even between embryonic stem cells and iPS cells (Barber et al. 
2005; Kim et al. 2012). However, in qualitative PCR even small amount ought to be 
sufficient for a positive result. 
 
PCR analyses in general showed variation in the initial result reliability. Some of the 
reactions had to be repeated several times before succeeding. Reasons to these problems 
are not evident and they may sporadical as well as systematic. Sporadical errors are likely 
to arise in PCR due to the sensitivity of the method and susceptibility to contamination. 
Preparation of fresh primer dilutions before master mix preparation seemed to improve 
results, indicating contamination problems. Both types of errors can however signal that 
the method is not robust enough. 
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Even though this may be attributable to and inherent in the method, some modifications 
can be speculated with. These include the use of previously mentioned reagents, DMSO 
and betaine to improve PCR efficiency especially with sequences containing high 
amounts of GC (Mammedov et al. 2008). The successful use of BSA as an enhancer in 
combination with other reagents has also been reported (Farell & Alexandre 2012). 
 
In agarose gels, some blanks and samples in general exhibited strong non-specific noise 
and primer-dimers (figure 12 (B), for instance). It was also noted that upper row samples 
in a two-row gel were systematically brighter than lower row samples (bright: figure 10 
A & C; dim: figure 10 B & D). This may be due to optical properties of the gel and might 
pose a problem if also weak bands are to be sought for. While not deemed necessary, 
nonspecific noise could possibly be reduced in gels using a mRNA-specific RNA 
isolation method or mRNA-specific cDNA-transcription primers rather than random 
primers. 
 
Although there were some slight differences between the Sendai-inducted and retrovirally 
inducted lines, such as the initial success with the PCR analysis, no difference can reliably 
be attributed to the difference in induction method on the basis of this data. As all required 
markers for pluripotency were identified and no transgene activity was observed, cells 
may be used as pluripotent stem cells in research protocols. It must however be noted that 
study of pluripotency does not sort out iPS cell lines with different disease-related 
genotypes and iPS cells and embryonic stem cells from each other. As contaminations 
may occur during cell culture and manipulation, these possibilities are to be searched with 
other methods. 
 
44 
 
REFERENCES 
Abraham, S., Sheridan, S. D., Miller, B. & Rao, R. R. 2010. Stable propagation of human 
embryonic and induced pluripotent stem cells on decellularized human substrates. 
Biotechnology Progress 4/2010, 1126-1134. 
 
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K. & Walter, P. 2008. Molecular 
Biology of the Cell. 5th edition. U.S.A.: Garland Publishing. 
 
Aoi, T., Yae, K., Nakagawa, M., Ichisaka, T., Okita, K., Takahashi, K., Chiba, T. & 
Yamanaka, S. 2008. Generation of pluripotent stem cells from adult mouse liver and 
stomach cells. Science 2008, 699-702.  
 
Ball, M. P. 2007. PCR [image]. Saved 24.10.2013. 
http://commons.wikimedia.org/wiki/File:PCR.svg 
 
Barber, R. D., Harmer, D. W., Coleman, R. A. & Clark, B. J. 2005. GAPDH as a 
housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human 
tissues. Physiological Genomics 3/2005, 389-395. 
 
Baskaran, N., Kandpal, R. P., Bhargava, A. K., Glynn, M. W., Bale, A. & Weissman, S. 
M. 1996. Uniform Amplification of a Mixture of Deoxyribonucleic Acids with Varying 
GC Content. Genome Research 7/1996, 633-638. 
 
Ben-Shushan, E., Thompson, J. R., Gudas, L. J. & Bergman, Y. 1998. Rex-1, a gene 
encoding a transcription factor expressed in the early embryo, is regulated via Oct-3/4 
and Oct-6 binding to an octamer site and a novel protein, Rox-1, binding to an adjacent 
site. Molecular and Cellular Biology 4/1998, 1866-1878. 
 
Bernas, T., Zarebski, M., Dobrucki, J. W. & Cook, P. R. 2004. Minimizing 
photobleaching during confocal microscopy of fluorescent probes bound to chromatin: 
role of anoxia and photon flux. Journal of microscopy 3/2004, 281-296.  
 
Campbell, M. K. & Farrell, S. O. 2012. Biochemistry. 7th edition. U.S.A.: Brooks/Cole. 
 
Chakrabarti, R. & Chakrabarti, R. 2001. Novel role of extracellular carbon dioxide in 
lymphocyte proliferation in culture. Journal of Cellular Biochemistry 2/2001, 200-203. 
 
Claassen, D. A., Desler, M. M. & Rizzino, A. 2009. ROCK inhibition enhances the re-
covery and growth of cryopreserved human embryonic stem cells and human induced 
pluripotent stem cells. Molecular reproduction and development 8/2009, 722-732. 
 
Eales, L-J. 2003. Immunology for Life Scientists. 2nd edition. United Kingdom: John 
Wiley & Sons. 
 
Eiselleova, L., Peterkova, I., Neradil, J., Slaninova, I., Hampl, A., Dvorak, P. 2008. 
Comparative study of mouse and human feeder cells for human embryonic stem cells. 
The International Journal of Developmental Biology 4/2008, 353-363. 
 
45 
 
Eminli, S., Utikal, J., Arnold, K., Jaenisch, R. & Hochedlinger, K. 2008. Reprogramming 
of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous 
Sox2 expression. Stem Cells 10/2008, 2467-2474.  
 
Farell, E. M. & Alexandre, G. 2012. Bovine serum albumin further enhances the effects 
of organic solvents on increased yield of polymerase chain reaction of GC-rich templates. 
BMC Research Notes 2012. 
 
Fusaki, N., Ban, H., Nishiyama, A., Saeki, A. & Hasegawa, M. 2009. Efficient induction 
of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an 
RNA virus that does not integrate into the host genome. The Proceedings of the Japan 
Academy, Series B, 8/2009, 348-362.  
 
Grskovic, M., Javaherian, A., Strulovici, B., Daley, G. Q. 2011. Induced pluripotent stem 
cells--opportunities for disease modelling and drug discovery. Nature Reviews Drug 
Discovery 12/2011, 915-929.  
 
Guenther, M. G., Frampton, G. M., Soldner, F., Hockemeyer, D.,Mitalipova, M., 
Jaenisch, R. & Young, R. A. 2010. Chromatin Structure and Gene Expression Programs 
of Human Embryonic and Induced Pluripotent Stem Cells. Cell Stem Cell 2/2010, 249-
257. 
 
Hanna, J., Markoulaki, S., Schorderet, P., Carey, B. W., Beard, C., Wernig, M., 
Creyghton, M. P., Steine, E. J., Cassady, J. P., Foreman, R., Lengner, C. J., Dausman, 
J.A. & Jaenisch, R. 2008. Direct reprogramming of terminally differentiated mature B 
lymphocytes to pluripotency. Cell 2/2008, 250-264. 
 
Huangfu, D., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, 
W. & Melton, D. A. 2008. Induction of pluripotent stem cells from primary human 
fibroblasts with only Oct4 and Sox2. Nature Biotechnology 11/2008, 1269-1275.  
 
Hyun, I., Hochedlinger, K., Jaenisch, R. & Yamanaka, S. 2007. New Advances in iPS 
Cell Research Do Not Obviate the Need for Human Embryonic Stem Cells. Cell Stem 
Cell 4/2007, 367-368. 
 
International Stem Cell Initiative. 2007. Characterization of human embryonic stem cell 
lines by the International Stem Cell Initiative. Nature Biotechnology 7/2007, 803-816.  
 
Jagtap, S., Meganathan, K., Gaspar, J., Wagh, V., Winkler, J., Hescheler, J & Sachinidis, 
A. 2011. Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in 
human embryonic stem cells during multilineage differentiation. British Journal of 
Pharmacology 8/2011, 1743-1756.  
 
Janeway, C. A. Jr., Travers, P., Walport, M. & Shlomchik, M. J. 2007. Immunobiology: 
the immune system in health and disease. 5th edition. U.S.A.: Garland Publishing.  
 
Jensen, M. A., Fukushima, M. & Davis, R. W. 2010. DMSO and Betaine Greatly Improve 
Amplification of GC-Rich Constructs in De Novo Synthesis. PLoS One 6/2010. 
 
  
46 
 
Kang, J., Lee, M. S., Gorenstein, D. G. 2005. The enhancement of PCR amplification of 
a random sequence DNA library by DMSO and betaine: application to in vitro 
combinatorial selection of aptamers. Journal of Biochemical and Biophysical Methods 
2/2005, 147-151. 
 
Kapuscinski, J. 1990. Interactions of nucleic acids with fluorescent dyes: spectral 
properties of condensed complexes. The Journal of Histochemistry and Cytochemistry 
9/1990, 1323-1329. 
 
Kenna, J. G., Major, G. N. & Williams, R. S. 1985. Methods for reducing non-specific 
antibody binding in enzyme-linked immunosorbent assays. Journal of Immunological 
Methods 2/1985, 409-419.  
 
Kim, J., Chu, J., Shen, X., Wang, J. & Orkinsend, S. H. 2008. An Extended 
Transcriptional Network for Pluripotency of Embryonic Stem Cells. Cell 6/2008, 1049-
1061. 
 
Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., Aryee, M. J., Ji, H., 
Ehrlich, L. I., Yabuuchi, A., Takeuchi, A., Cunniff, K. C., Hongguang, H., McKinney-
Freeman, S., Naveiras, O., Yoon, T. J., Irizarry, R. A., Jung, N., Seita, J., Hanna, J., 
Murakami, P., Jaenisch, R., Weissleder, R., Orkin, S. H., Weissman, I. L., Feinberg, A. 
P. & Daley, G. Q. 2010. Epigenetic memory in induced pluripotent stem cells. Nature 
2010, 285-290. 
 
Kim, S. Y., Kim, M. J., Jung, H., Kim, W. K., Kwon, S. O., Son, M. J., Jang, I. S., Choi, 
J. S., Park, S. G., Park, B. C., Han, Y. M., Lee, S. C., Cho, Y. S., Bae, K. H. 2012. 
Comparative proteomic analysis of human somatic cells, induced pluripotent stem cells, 
and embryonic stem cells. Stem Cells and Development 8/2012, 1272-1286. 
 
Kolios, G. & Moodley, Y. 2013. Introduction to stem cells and regenerative medicine. 
Respiration 1/2013, 3-10. 
 
Kurosawa, H. 2007. Methods for inducing embryoid body formation: in vitro 
differentiation system of embryonic stem cells. Journal of Bioscience and Bioengineering 
5/2007, 389-398.  
 
Larsen, T. A., Goodsell, D.S., Cascio, D., Grzeskowiak, K. & Dickerson, R. E. 1989. The 
structure of DAPI bound to DNA. Journal of biomolecular structure & dynamics 3/1989, 
477-491. 
 
Levenstein, M. E., Ludwig, T. E., Xu, R. H., Llanas, R. A., VanDenHeuvel-Kramer, K., 
Manning, D., Thomson, J. A. 2006. Basic fibroblast growth factor support of human 
embryonic stem cell self-renewal. Stem Cells 3/2006, 568-574. 
 
Life Technologies. 2013. The Alexa Fluor Dye Series—Note 1.1. Printed 14.11.2013. 
http://www.lifetechnologies.com/fi/en/home/references/molecular-probes-the-
handbook/technical-notes-and-product-highlights/the-alexa-fluor-dye-series.html 
 
Longin, A., Souchier, C., Ffrench, M. & Bryon, P-A. 1993. Comparison of anti-fading 
agents used in fluorescence microscopy: image analysis and laser confocal microscopy 
study. The Journal of Histochemistry and Cytochemistry, 12/1993, 1833-1840. 
47 
 
Lovell-Badge, R. 2007. Many ways to pluripotency. Nature Biotechnology 10/2007, 
1114-1116. 
 
Macherey-Nagel. 2011. Total RNA isolation. User manual. Rev. 13. Printed 20.8.2013. 
http://www.clontech.com/xxclt_ibcGetAttachment.jsp?cItemId=17426 
 
Maherali, N., Sridharan, R., Xie, W., Utikal, J., Eminli, S., Arnold, K., Stadtfeld, M., 
Yachechko, R., Tchieu, J., Jaenisch, R., Plath, K. & Hochedlinger. K. 2007. Directly 
reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue 
contribution. Cell Stem Cell 1/2007, 55-70. 
 
Mammedov, T. G., Pienaar, E., Whitney, S. E., TerMaat, J. R., Carvill, G., Goliath, R., 
Subramanian, A. & Viljoen, H. J. 2008. A Fundamental Study of the PCR Amplification 
of GC-Rich DNA Templates. Computational Biology and Chemistry 6/2008, 452-457. 
 
Mitalipov, S. & Wolf, D. 2009. Totipotency, Pluripotency and Nuclear Reprogramming. 
Advances in Biochemical Engineering / Biotechnology 2009, 185-199. 
 
Miyazaki, S., Yamamoto, H., Miyoshi, N., Takahashi, H., Suzuki, Y., Haraguchi, N., 
Ishii, H., Doki, Y. & Mori, M. 2012. Emerging methods for preparing iPS cells. Japanese 
Journal of Clinical Oncology 9/2012, 773-779.  
 
Munch, D. 2007. Schematic diagram of primary and secondary antibody binding [image]. 
Saved 21.11.2013.  
http://commons.wikimedia.org/wiki/File:Primary-Secondaryantibody.svg 
 
Muyal, J. P., Muyal, V., Kaistha B. P., Seifart, C. & Fehrenbach, H. 2009. Systematic 
comparison of RNA extraction techniques from frozen and fresh lung tissues: checkpoint 
towards gene expression studies. Diagnostic Pathology 9/2009. 
 
Ng, V. Y. & Choo, A. B. H. 2010. iPS and ES Cells: Do Both Roads Lead to Rome? The 
Open Stem Cell Journal 1/2010, 8-17. 
 
Niakan, K. K., Ji, H., Maehr, R., Vokes, S. A., Rodolfa, K. T., Sherwood, R. I., Yamaki, 
M., Dimos, J. T., Chen, A. E., Melton, D. A., McMahon, A. P. & Eggan, K. 2010. Sox17 
promotes differentiation in mouse embryonic stem cells by directly regulating 
extraembryonic gene expression and indirectly antagonizing self-renewal. Genes & 
Development 3/2010, 312-326. 
 
Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., Wang, R., Green, D. R., 
Tessarollo, L., Casellas, R., Zhao, K. & Levens, D. 2012. c-Myc is a universal amplifier 
of expressed genes in lymphocytes and embryonic stem cells. Cell 1/2012, 68-79. 
 
Okita, K., Ichisaka, T. & Yamanaka, S. 2007. Generation of germline-competent induced 
pluripotent stem cells. Nature 2007, 313-317. 
 
Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T. & Yamanaka, S. 2008. Generation 
of mouse induced pluripotent stem cells without viral vectors. Science 2008, 949-953. 
  
48 
 
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., 
Nakagawa, M., Tanabe, K., Tezuka, K., Shibata, T., Kunisada, T., Takahashi, M., 
Takahashi, J., Saji, H., Yamanaka, S. 2011. A more efficient method to generate 
integration-free human iPS cells. Nature Methods 5/2011, 409-412. 
 
Ono, M., Murakami, T., Kudo, A., Isshiki, M., Sawada, H. & Segawa, A. 2001. 
Quantitative comparison of anti-fading mounting media for confocal laser scanning 
microscopy. The Journal of Histochemistry and Cytochemistry, 3/2001, 305-312. 
 
Panchuk-Voloshina, N., Haugland, R. P., Bishop-Stewart, J., Bhalgat, M. K., Millard, P. 
J., Mao, F., Leung, W-Y. & Haugland, R. P. 1999. Alexa Dyes, a Series of New 
Fluorescent Dyes that Yield Exceptionally Bright, Photostable Conjugates. Journal of 
Histochemistry & Cytochemistry 9/1999, 1179-1188. 
 
Park, I. H., Lerou, P. H., Zhao, R., Huo, H. & Daley, G. Q. 2008. Generation of human-
induced pluripotent stem cells. Nature Protocols 7/2008, 1180-1186. 
 
Pekkanen-Mattila, M., Ojala, M., Kerkelä, E., Rajala, K., Skottman, H., Aalto-Setälä, K. 
2012. The effect of human and mouse fibroblast feeder cells on cardiac differentiation of 
human pluripotent stem cells. Stem Cells International 2012. 
 
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., 
Moorman, M. A., Simonetti, D. W., Craig, S. & Marshak, D. R. 1999. Multilineage 
potential of adult human mesenchymal stem cells. Science 1999, 143-147. 
 
Poudel, B., Bilbao, D., Sarathchandra, P., Germack, R., Rosenthal, N. & Santini, M. P. 
2011. Increased cardiogenesis in P19-GFP teratocarcinoma cells expressing the 
propeptide IGF-1Ea. Biochemical and Biophysical Research Communications 3-4/2011, 
293-299. 
 
Rajala, K., Lindroos, B., Hussein, S. M., Lappalainen, R. S., Pekkanen-Mattila, M., 
Inzunza, J., Rozell, B., Miettinen, S., Narkilahti, S., Kerkelä, E., Aalto-Setälä, K., 
Otonkoski, T., Suuronen, R., Hovatta, O & Skottman H. 2010. A Defined and Xeno-Free 
Culture Method Enabling the Establishment of Clinical-Grade Human Embryonic, 
Induced Pluripotent and Adipose Stem Cells. PLoS One, 4/2010. 
 
Rizzino, A. 2009. Sox2 and Oct-3/4: A Versatile Pair of Master Regulators that 
Orchestrate the Self-renewal and Pluripotency of Embryonic Stem Cells by Functioning 
as Molecular Rheostats. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 
2/2009, 228-236. 
 
Robinton, D. A. & Daley, G. Q. 2012. The promise of induced pluripotent stem cells in 
research and therapy. Nature 2012, 295-305. 
 
Rodolfa, K. T. 2008. Inducing pluripotency [image]. Saved 10.11.2013. 
http://www.stembook.org/node/514 
 
Schopperle, W. M. & DeWolf, W. C. 2007. The TRA-1-60 and TRA-1-81 human 
pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. 
Stem Cells 3/2007, 723-730. 
 
49 
 
Schroeder, I. S., Sulzbacher, S., Nolden, T., Fuchs, J., Czarnota, J., Meisterfeld, R., 
Himmelbauer, H. & Wobus A. M. 2012. Induction and selection of Sox17-expressing 
endoderm cells generated from murine embryonic stem cells. Cells Tissues Organs 
6/2012, 507-523. 
 
Shi, W., Wang, H., Pan, G., Geng, Y., Guo, Y. & Pei, D. 2006. Regulation of the 
pluripotency marker Rex-1 by Nanog and Sox2. The Journal of Biological Chemistry 
33/2006, 23319-23325. 
 
Seaberg, R. M. & van der Kooy, D. 2003. Stem and progenitor cells: the premature 
desertion of rigorous definitions. Trends in Neurosciences, 3/2003, 125-131. 
 
Stadtfeld, M. & Hochedlinger, K. 2010. Induced pluripotency: history, mechanisms, and 
applications. Genes & Development 20/2010, 2239-2273. 
 
Surmacz, B., Fox, H., Gutteridge, A., Lubitz, S. & Whiting, P. 2012. Directing 
Differentiation of Human Embryonic Stem Cells Toward Anterior Neural Ectoderm 
Using Small Molecules. Stem Cells 9/2012, 1875-1884. 
 
Takahashi, K. & Yamanaka, S. 2006. Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 4/2006, 663-676. 
 
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. & 
Yamanaka, S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by 
defined factors. Cell 5/2007, 861-872. 
 
Takenaga, M., Fukumoto, M. & Hori, Y. 2007. Regulated Nodal signaling promotes 
differentiation of the definitive endoderm and mesoderm from ES cells. Journal of Cell 
Science 12/2007, 2078-2090. 
 
Tambe, Y. 2007. Induction of iPS cells [image]. Wikimedia Commons. Saved 
10.11.2013. http://commons.wikimedia.org/wiki/File:Induction_of_iPS_cells.svg 
 
Theunissen, T. W. & Silva, J. C. 2011. Switching on pluripotency: a perspective on the 
biological requirement of Nanog. Philosophical Transactions of the Royal Society B: 
Biological Sciences 2011, 2222-2229. 
 
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., 
Marshall, V.S. & Jones, J. M. 1998. Embryonic stem cell lines derived from human 
blastocysts. Science 1998, 1145-1147. 
 
Tiscornia, G., Vivas, E. L., Izpisúa Belmonte, J. C. 2011. Diseases in a dish: modeling 
human genetic disorders using induced pluripotent cells. Nature Medicine 12/2011, 1570-
1576. 
 
Toivonen, S., Ojala, M., Hyysalo, A., Ilmarinen, T., Rajala, K., Pekkanen-Mattila, M., 
Äänismaa, R., Lundin, K., Palgi, J., Weltner, J., Trokovic, R., Silvennoinen, O., 
Skottman, H., Narkilahti, S., Aalto-Setälä, K., Otonkoski, T. 2013. Comparative analysis 
of targeted differentiation of human induced pluripotent stem cells (hiPSCs) and human 
embryonic stem cells reveals variability associated with incomplete transgene silencing 
in retrovirally derived hiPSC lines. Stem Cells Translational Medicine 2/2013, 83-93. 
 
50 
 
Vallier, L., Alexander, M., Pedersen, R. A. 2005. Activin/Nodal and FGF pathways 
cooperate to maintain pluripotency of human embryonic stem cells. Journal of Cell 
Science 19/2005, 4495-4509. 
 
Varas, F., Stadtfeld, M., de Andres-Aguayo, L., Maherali, N., di Tullio, A., Pantano, L., 
Notredame, C., Hochedlinger, K. & and Graf, T. 2009. Fibroblast-Derived Induced 
Pluripotent Stem Cells Show No Common Retroviral Vector Insertions. Stem Cells 
2/2009, 300-306. 
 
Vomelová, I., Vaníčková, Z. & Šedo, A. 2009. Methods of RNA Purification: All Ways 
(Should) Lead to Rome. Folia Biologica 6/2009, 243-251. 
 
Wang, P., Rodriguez, R. T., Wang, J., Ghodasara, A. & Kim, S. K. 2011. Targeting 
SOX17 in Human Embryonic Stem Cells Creates Unique Strategies for Isolating and 
Analyzing Developing Endoderm. Cell Stem Cell, 3/2011, 335-346. 
 
Warrington, J. A., Nair, A., Mahadevappa, M. & Tsyganskaya, M. 2000. Comparison of 
human adult and fetal expression and identification of 535 housekeeping/maintenance 
genes. Physiological Genomics 3/2000, 143-147. 
 
Watson, J. D., Baker, T. A., Bell, S. P., Gann, A., Levine, M. & Losick, R. 2004. 
Molecular Biology of the Gene. 5th edition. U.S.A.: Pearson Education. 
 
Wei, Z., Yang, Y., Zhang, P., Andrianakos, R., Hasegawa, K., Lyu, J., Chen, X., Bai, G., 
Liu, C., Pera, M. & Lu, W. 2009. Klf4 interacts directly with Oct4 and Sox2 to promote 
reprogramming. Stem Cells 12/2009, 2969-2978. 
 
Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger, K., 
Bernstein, B. E. & Jaenisch, R. 2007. In vitro reprogramming of fibroblasts into a 
pluripotent ES-cell-like state. Nature 2007, 318-324.  
 
Wheeler, R. 2013. Diagrammatic representation of the primers for PCR [image]. Saved 
10.11.2013. http://commons.wikimedia.org/wiki/File:Primers_RevComp.svg 
 
Wikimedia Commons. 2007. Antibody [image]. Saved 10.11.2013. 
http://commons.wikimedia.org/wiki/File:Antibody.svg 
 
Wikimedia Commons. 2008. Qiagen Mini Spin Column [image]. Saved 16.11.2013. 
http://commons.wikimedia.org/wiki/File:Qiagen_Mini_Spin_Column.svg 
 
Wilson, K. & Walker, J. (ed.) 2010. Principles and Techniques of Biochemistry and 
Molecular Biology. 7th edition. U.S.A.: Cambridge University Press. 
 
Yamanaka, S. 2007. Strategies and New Developments in the Generation of Patient-
Specific Pluripotent Stem Cells. Cell Stem Cell 1/2007, 39-49. 
 
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., 
Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., Slukvin, I. I. & Thomson, J. A. 2007. 
Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 
1917-1920. 
 
51 
 
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., Thomson, J. A. 2009. 
Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences. Science 
2009, 797-801. 
 
52 
 
APPENDICES 
Appendix 1. Media contents. 
 
Contents of 50 ml aliquot of KSR medium. 
KnockOut™ DMEM (KO-DMEM) 38,65 ml 
KnockOut™ serum replacement (KO-SR) 10 ml 
GlutaMax™ 0,5 ml 
Non-essential amino acids (NEAA) 0,5 ml 
Penicillin/Streptomycin 0,25 ml 
β-mercaptoethanol 98 µl 
FGF (7,8 µg/ml) 26 µl 
 
Contents of 50 ml aliquot of MEF medium. 
KnockOut™ DMEM (KO-DMEM) 44,5 ml 
FBS (fetal bovine serum) 5 ml 
GlutaMax™ 0,5 ml 
Medium is sterile filtered. 
 
Freezing medium contents for 0,5 ml. 
FBS, fetal bovine serum 90 %, 450 µl 
DMSO, dimethyl sulfoxide 10 %, 50 µl 
ROCK (rho-associated protein kinase) inhibitor 0,5 µl 
 
Contents of 50 ml aliquot of embryoid body medium. 
KnockOut™ DMEM (KO-DMEM) 28,65 ml 
KnockOut™ serum replacement (KO-SR) 20 ml 
GlutaMax™ (Life Technologies) 0,5 ml 
Non-essential amino acids (NEAA) 0,5 ml 
Penicillin/Streptomycin 0,25 ml 
β-mercaptoethanol 98 µl 
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Appendix 2. Fluorescence staining additional data. 
 
 
Fluorescence staining sample passages. 
Cell line  Passage 
UTA.07001.CPVT 26 
UTA.05303.CPVT 14 
UTA.05404.CPVT 30 
UTA.02912.HCMTs 10 
UTA.01402.HCMTs 10 
UTA.11505.WTsb 32 
 
 
Fluorescence staining solutions. 
Solution Contents 
PBS Phosphate buffered saline, [PO43-] = 0,01 M, pH = 7,4 
4 % PFA 4 % w/v paraformaldehyde in purified water, filtered 
Blocking solution 10 % normal donkey serum, 0,1 % Triton X-100, 1 % 
bovine serum albumin in PBS 
Primary Ab + washing 
solution 
1 % normal donkey serum, 0,1 % Triton X-100, 1 % 
bovine serum albumin in PBS 
Secondary Ab + washing 
solution 
1 % bovine serum albumin in PBS 
PB Phosphate buffer, [PO43-] = 0,01 M, pH = 7,4 
Mounting solution Vectashield® with DAPI (Vector Laboratories) 
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Appendix 3. Pipetting charts for PCR.                                                                         1 (4) 
 
Pipetting chart for transgenes 
 
well upper row  well lower row  
1 standard  1 standard  
2 07001.CPVT  p. 15 GAPDH 2 07001.CPVT  p. 15 exo SOX2 
3 05303.CPVT  p. 13 GAPDH 3 05303.CPVT  p. 13 exo SOX2 
4 05404.CPVT  p. 19 GAPDH 4 05404.CPVT  p. 19 exo SOX2 
5   5 positive control exo SOX2 
6   6   
7 07001.CPVT  p. 15 exo c-Myc 7   
8 05303.CPVT  p. 13 exo c-Myc 8 07001.CPVT  p. 15 exo OCT3/4 
9 05404.CPVT  p. 19 exo c-Myc 9 05303.CPVT  p. 13 exo OCT3/4 
10 positive control exo c-Myc 10 05404.CPVT  p. 19 exo OCT3/4 
11   11 positive control exo OCT3/4 
12   12   
13 07001.CPVT  p. 15 exo Klf4 13   
14 05303.CPVT  p. 13 exo Klf4 14 H2O (cDNA) GAPDH 
15 05404.CPVT  p. 19 exo Klf4 15 no RT exo c-Myc 
16 positive control exo Klf4 16 H2O (PCR) exo c-Myc 
 
 
well upper row  well lower row  
1 standard  1 standard  
2 02912.HCMTs  p. 14 exo OCT3/4 2 02912.HCMTs  p. 14 exo SOX2 
3 01401.HCMTs  p. 9 exo OCT3/4 3 01401.HCMTs  p. 9 exo SOX2 
4 01402.HCMTs  p. 10 exo OCT3/4 4 01402.HCMTs  p. 10 exo SOX2 
5 11505.WTsb  p. 29 exo OCT3/4 5 11505.WTsb  p. 29 exo SOX2 
6 positive control exo OCT3/4 6 positive control exo SOX2 
7    7    
8    8    
9 02912.HCMTs  p. 14 exo Klf4 9 02912.HCMTs  p. 14 exo c-Myc 
10 01401.HCMTs  p. 9 exo Klf4 10 01401.HCMTs  p. 9 exo c-Myc 
11 01402.HCMTs  p. 10 exo Klf4 11 01402.HCMTs  p. 10 exo c-Myc 
12 11505.WTsb  p. 29 exo Klf4 12 11505.WTsb  p. 29 exo c-Myc 
13 positive control exo Klf4 13 positive control exo c-Myc 
14    14   
15    15   
16 02912.HCMTs  p. 14 GAPDH 16 H2O (cDNA) GAPDH 
17 01401.HCMTs  p. 9 GAPDH 17 no RT exo c-Myc 
18 01402.HCMTs  p. 10 GAPDH 18 H2O (PCR) exo c-Myc 
19 11505.WTsb  p. 29 GAPDH 19   
20 positive control GAPDH 20   
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Pipetting chart for endogenous pluripotency markers                          2 (4) 
 
well upper row primers 
1 standard  
2 07001.CPVT  p. 27 Nanog 
3 07001.CPVT  p. 27 OCT3/4 
4 07001.CPVT  p. 27 SOX2 
5 07001.CPVT  p. 27 GAPDH 
6 07001.CPVT  p. 27 Rex1 
7 07001.CPVT  p. 27 c-Myc 
8   
9   
10 05404.CPVT  p. 31 Nanog 
11 05404.CPVT  p. 31 GAPDH 
12 05404.CPVT  p. 31 Rex1 
13 05404.CPVT  p. 31 OCT3/4 
14 05404.CPVT  p. 31 SOX2 
15 05404.CPVT  p. 31 c-Myc 
16   
17   
18 H2O (cDNA) Rex1 
19 no RT Nanog 
20 H2O (PCR) c-Myc 
 
 
well upper row primers 
1 standard  
2 11505.WTsb  p. 29 Nanog 
3 11505.WTsb  p. 29 GAPDH 
4 11505.WTsb  p. 29 Rex1 
5 11505.WTsb  p. 29 OCT3/4 
6 11505.WTsb  p. 29 SOX2 
7 11505.WTsb  p. 29 c-Myc 
8   
9   
10 05303.CPVT  p. 13 Nanog 
11 05303.CPVT  p. 13 GAPDH 
12 05303.CPVT  p. 13 Rex1 
13 05303.CPVT  p. 13 OCT3/4 
14 05303.CPVT  p. 13 SOX2 
15 05303.CPVT  p. 13 c-Myc 
16   
17   
18 H2O (cDNA) Rex1 
19 no RT Nanog 
20 H2O (PCR) c-Myc 
 
well lower row primers 
1 standard  
2 11505.WTsb  p. 29 β-actin 
3 11505.WTsb  p. 29 OCT3/4 
4   
5 05303.CPVT  p. 13 β-actin 
6 05303.CPVT  p. 13 OCT3/4 
7   
8   
9 H2O (cDNA) β-actin 
10 no RT β-actin 
11 H2O (PCR) β-actin 
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3 (4) 
well upper row primers 
1 standard  
2 02912.HCMTs  p. 14 Nanog 
3 02912.HCMTs  p. 14 GAPDH 
4 02912.HCMTs  p. 14 Rex1 
5 02912.HCMTs  p. 14 OCT3/4 
6 02912.HCMTs  p. 14 SOX2 
7 02912.HCMTs  p. 14 c-Myc 
8   
9   
10 01402.HCMTs  p. 10 Nanog 
11 01402.HCMTs  p. 10 GAPDH 
12 01402.HCMTs  p. 10 Rex1 
13 01402.HCMTs  p. 10 OCT3/4 
14 01402.HCMTs  p. 10 SOX2 
15 01402.HCMTs  p. 10 c-Myc 
16   
17   
18 H2O (cDNA) Rex1 
19 no RT Nanog 
20 H2O (PCR) c-Myc 
 
 
 
 
Pipetting charts for embryoid body samples 
 
well upper row primers well lower row primers 
1 standard  1 standard  
2 07001.CPVT  p. 15 SOX17 2 05404.CPVT  p. 18 SOX17 
3 07001.CPVT  p. 15 α-cardiac actinin 3 05404.CPVT  p. 18 α-cardiac actinin 
4 07001.CPVT  p. 15 Nestin 4 05404.CPVT  p. 18 Nestin 
5 07001.CPVT  p. 15 AFP 5 05404.CPVT  p. 18 AFP 
6 07001.CPVT  p. 15 PAX6 6 05404.CPVT  p. 18 PAX6 
7 07001.CPVT  p. 15 GAPDH 7 05404.CPVT  p. 18 GAPDH 
8 07001.CPVT  p. 15 VEGFR2/KDR 8 05404.CPVT  p. 18 VEGFR2/KDR 
9   9   
10   10   
11 H2O (cDNA) VEGFR2/KDR 11   
12 no RT VEGFR2/KDR 12   
13 H2O (PCR) VEGFR2/KDR 13   
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4 (4) 
well upper row primers well lower row primers 
1 standard  1 standard  
2 05303.CPVT  p. 11 SOX17 2 11505.WTsb  p. 33 SOX17 
3 05303.CPVT  p. 11 α-cardiac actinin 3 11505.WTsb  p. 33 α-cardiac actinin 
4 05303.CPVT  p. 11 Nestin 4 11505.WTsb  p. 33 Nestin 
5 05303.CPVT  p. 11 AFP 5 11505.WTsb  p. 33 AFP 
6 05303.CPVT  p. 11 PAX6 6 11505.WTsb  p. 33 PAX6 
7 05303.CPVT  p. 11 GAPDH 7 11505.WTsb  p. 33 GAPDH 
8 05303.CPVT  p. 11 VEGFR2/KDR 8 11505.WTsb  p. 33 VEGFR2/KDR 
9   9   
10   10   
11 H2O (cDNA) VEGFR2/KDR 11   
12 no RT VEGFR2/KDR 12   
13 H2O (PCR) VEGFR2/KDR 13   
 
 
well upper row primers well lower row primers 
1 standard  1 standard  
2 01402.HCMTs p. 10 SOX17 2 02912.HCMTs p. 13 SOX17 
3 01402.HCMTs p. 10 α-cardiac actinin 3 02912.HCMTs p. 13 α-cardiac actinin 
4 01402.HCMTs p. 10 Nestin 4 02912.HCMTs p. 13 Nestin 
5 01402.HCMTs p. 10 AFP 5 02912.HCMTs p. 13 AFP 
6 01402.HCMTs p. 10 PAX6 6 02912.HCMTs p. 13 PAX6 
7 01402.HCMTs p. 10 GAPDH 7 02912.HCMTs p. 13 GAPDH 
8 01402.HCMTs p. 10 VEGFR2/KDR 8 02912.HCMTs p. 13 VEGFR2/KDR 
9   9   
10   10   
11 H2O (cDNA) VEGFR2/KDR 11   
12 no RT VEGFR2/KDR 12   
13 H2O (PCR) VEGFR2/KDR 13   
 
 
